These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27349028)

  • 1. Reflexive Screening for BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia.
    Langabeer SE; McCarron SL; Haslam K; Preston L
    Clin Lab; 2016; 62(5):975-6. PubMed ID: 27349028
    [No Abstract]   [Full Text] [Related]  

  • 2. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
    Soverini S; Branford S; Nicolini FE; Talpaz M; Deininger MW; Martinelli G; Müller MC; Radich JP; Shah NP
    Leuk Res; 2014 Jan; 38(1):10-20. PubMed ID: 24131888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCR-ABL1 mutation screening in chronic myeloid leukaemia: is next now?
    Soverini S; Martelli M; Bavaro L
    Lancet Haematol; 2019 May; 6(5):e236-e237. PubMed ID: 31036315
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.
    Baccarani M; Soverini S; De Benedittis C
    Am Soc Clin Oncol Educ Book; 2014; ():167-75. PubMed ID: 24857074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
    Oyekunle AA; Castagnetti F; Gugliotta G; Soverini S; Baccarani M; Rosti G
    Leuk Res; 2011 Jul; 35(7):e118-20. PubMed ID: 21489624
    [No Abstract]   [Full Text] [Related]  

  • 6. Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.
    Soverini S; de Benedittis C; Mancini M; Martinelli G
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S120-8. PubMed ID: 26297264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness of interferon-α combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.
    Zhang H; Liang Z; Hu Y; Wang X; Wang B; Huang H
    Leuk Lymphoma; 2018 Dec; 59(12):3018-3019. PubMed ID: 29616854
    [No Abstract]   [Full Text] [Related]  

  • 8. Prolonged treatment-free remission in chronic myeloid leukemia patients with previous
    Claudiani S; Apperley JF; Khan A; Khorashad J; Milojkovic D
    Haematologica; 2020 May; 105(5):e225-e227. PubMed ID: 31537692
    [No Abstract]   [Full Text] [Related]  

  • 9. Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India.
    Kuila N; Dash N; Sahoo DP; Pattnayak NC; Biswas G; Chakraborty S
    Leuk Lymphoma; 2009 Apr; 50(4):663-6. PubMed ID: 19373669
    [No Abstract]   [Full Text] [Related]  

  • 10. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
    Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
    BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia.
    Langabeer SE; Haslam K; Crampe M; MacDonagh B; McHugh J
    Exp Oncol; 2019 Mar; 41(1):82-83. PubMed ID: 30932408
    [No Abstract]   [Full Text] [Related]  

  • 12. Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
    Markose P; Chendamarai E; Balasubramanian P; Velayudhan SR; Srivastava VM; Mathews V; George B; Viswabandya A; Srivastava A; Chandy M
    Leuk Lymphoma; 2009 Dec; 50(12):2092-5. PubMed ID: 19925053
    [No Abstract]   [Full Text] [Related]  

  • 13. BCR-ABL1 compound mutations drive ponatinib resistance.
    Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.
    Zabriskie MS; Eide CA; Yan D; Vellore NA; Pomicter AD; Savage SL; Druker BJ; Deininger MW; O'Hare T
    Leukemia; 2016 Jun; 30(6):1418-21. PubMed ID: 26582647
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel
    Malik S; Hassan S; Eşkazan AE
    Expert Rev Hematol; 2021 Nov; 14(11):975-978. PubMed ID: 34608829
    [No Abstract]   [Full Text] [Related]  

  • 16. Chronic myeloid leukemia: Global impact from a local laboratory.
    Radich JP
    Cancer; 2017 Jul; 123(14):2594-2596. PubMed ID: 28586121
    [No Abstract]   [Full Text] [Related]  

  • 17. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
    Yang K; Fu LW
    Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
    Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
    Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.
    Beel K; Janssens A; Verhoef G; Vandenberghe P
    Leuk Res; 2009 Dec; 33(12):1703-5. PubMed ID: 19457553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.